Page 3 - Pharma Market

Seven of top 10 drug brands sold in India are from multinational companies

The top 10 corporates contribute to 43% of the domestic pharma market

Will close $150-mn funding in 3-5 months: Medlife CEO Ananth Narayanan

MedLife has seen 100 per cent year-on-year growth. It has built very unique assets that are not there with other players

Our aim is to be a global leader in biosimilars biz: Biocon Biologics CEO

Margins of biologics stood at 38% in Q1 as compared to 33% in the preceding quarter

Pfizer may be talks to merge off-patent drugs business with Mylan

Separation of Pfizer's off-patent business would be a tax-free spin-off

Right prescription

Being highly regulated, brands are wary about being too adventurous online

India's leadership in cost-efficient generics is unchallenged: Sanjiv Kaul

Price erosion has been in excess of 15 per cent last year and will perhaps be at similar levels this year due to sales channel consolidation, says Kaul

Pharma market to lose Rs 647 cr from drug price ceiling

The cardiac segment is the most hit, with a loss pegged at Rs 250 crore.

Drug ban may erode 12% of pharma market turnover

About Rs 12,000 cr of the roughly Rs 1 lakh cr turnover of market would be impacted